Founded in 1897, Biomnis, formerly Laboratoire Marcel Mérieux, is a provider of pathological analysis in the fields of molecular diagnostics, tissue, fertility treatment and specialised biochemistry.
It provides services on behalf of laboratories throughout France, operating two specialist sites in Paris and Lyon, with further sites in Paris, Lyon, Bordeaux, Dublin and Dubai. The group also owns a fully integrated logistics operation, TSE, handling five million samples per annum, collected daily throughout France.
Biomnis employs over 1,700 staff, a large proportion of whom are highly skilled scientists and biologists. We acquired Biomnis in November 2008.
Unusually for Duke Street, Biomnis was acquired through an auction process. However, the strong relationship we developed with the incumbent CEO, Jean-Louis Oger, meant we were able to work closely with the management team over a number of months to carry out extensive due diligence and to develop the appropriate plan for the business.
The specialist medical diagnostics market is extensive and valued at more than €6.5 billion. An attractive sector with its focus on illness prevention rather than cure. Within this market, Biomnis is the natural partner for over 4,000 local laboratories throughout France, providing opportunities for organic growth.
Together with management, we identified several opportunities to accelerate Biomnis’ growth, including introducing a comprehensive profitability plan which will bring the company’s profit margins in line with competitors. In addition, we decided to take advantage from regulatory changes to consolidate the French lab testing market through the synergetic acquisition of town laboratories.
It provides services on behalf of laboratories throughout France, operating two specialist sites in Paris and Lyon, with further sites in Paris, Lyon, Bordeaux, Dublin and Dubai. The group also owns a fully integrated logistics operation, TSE, handling five million samples per annum, collected daily throughout France.
Biomnis employs over 1,700 staff, a large proportion of whom are highly skilled scientists and biologists. We acquired Biomnis in November 2008.
Unusually for Duke Street, Biomnis was acquired through an auction process. However, the strong relationship we developed with the incumbent CEO, Jean-Louis Oger, meant we were able to work closely with the management team over a number of months to carry out extensive due diligence and to develop the appropriate plan for the business.
The specialist medical diagnostics market is extensive and valued at more than €6.5 billion. An attractive sector with its focus on illness prevention rather than cure. Within this market, Biomnis is the natural partner for over 4,000 local laboratories throughout France, providing opportunities for organic growth.
Together with management, we identified several opportunities to accelerate Biomnis’ growth, including introducing a comprehensive profitability plan which will bring the company’s profit margins in line with competitors. In addition, we decided to take advantage from regulatory changes to consolidate the French lab testing market through the synergetic acquisition of town laboratories.